View article

The glucose analog 2-deoxy-2-18F-D-glucose (FDG) is the most widely used radiopharmaceutical for imaging of cancers using PET. 18F-FDG is transported into tissues by glucose transporters (GLUTs) and is intracellularly phosphorylated into 18F-FDG-6-phosphate. The greater glucose demand required to sustain anaerobic metabolism in tumor cells results in upregulation of non-insulindependent transporters, GLUT-1 and GLUT-3. Since most neoplasms have low concentrations of glucose 6-phosphatase, 18F-FDG-6-phosphate accumulates in tumor cells, which results in enhanced tumor-to-background activity. Gastric cancer (GC) is a prevalent gastrointestinal malignancy and is the fourth leading cause of cancer-related deaths worldwide. 1 Although less deadly, colorectal cancer (CRC) is the most common malignancy of the gastrointestinal tract and is the third most common malignancy worldwide. GC and …